A Bridging Study of the SYN023 on Healthy Adult Subjects

NCT04495569 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Communicable Disease Transmission
Zoonotic Disease
Rabies Human
Vaccine Reaction
Immunisation Reaction

Interventions

BIOLOGICAL: recombinant anti-rabies human monoclonal antibody injection (SYN023)
BIOLOGICAL: Rabies Vaccine

Sponsor

Synermore Biologics (Suzhou) Co., Ltd.